SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

IM-1021

IMNM·Immunome Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1
Time to market
IM-1021 is in Phase 1 dose-escalation; assuming successful development, potential approval would be several years away (likely 2029-2030 at the earliest).
Why 4/10
The next hard catalyst is the ASH 2026 conference presentation in December 2026, where detailed initial Phase 1 data will be shared. However, IM-1021 is a Phase 1 asset and not Immunome's lead value driver (that is varegacestat, PDUFA April 28, 2027), so the impact score is moderate.
Actionable Insight NEUTRAL

The next catalyst for IM-1021 is the ASH 2026 conference in December 2026, where initial Phase 1 data will be presented in detail. The early 53% response rate is encouraging for a Phase 1 dose-escalation study, but the stock's larger binary event is the varegacestat PDUFA date of April 28, 2027. Watch for ASH abstract details and any expansion cohorts or dose-confirmation data that could signal registrational intent.

Price Chart

Loading chart...

Executive Summary

IM-1021 is Immunome's Phase 1 ROR1-targeted antibody-drug conjugate (ADC) for advanced B-cell non-Hodgkin lymphomas. Initial data announced in November 2026 showed a 53% objective response rate across all dose levels in heavily pretreated patients, including complete responses. The full dataset will be presented at the ASH 2026 conference in December 2026. IM-1021 is one of several pipeline assets at Immunome, which is primarily valued for its lead drug varegacestat (PDUFA April 28, 2027 for desmoid tumors). The company has a strong analyst consensus (21 analysts, mostly Buy/Strong Buy) with a mean price target of $35.20 (84.6% upside), but Q3 2026 results missed estimates and analysts trimmed forecasts. Insider selling and mixed institutional activity add caution to an otherwise bullish narrative.

How It Works

IM-1021 is an antibody-drug conjugate (ADC), a type of targeted cancer therapy. It works like a guided missile: the antibody portion binds to a protein called ROR1 found on the surface of certain cancer cells (including B-cell lymphomas and some solid tumors). Once attached, the drug is absorbed into the cancer cell, where it releases a chemotherapy payload (a TOP1 inhibitor) that damages the cell's DNA and kills it. This approach aims to deliver the chemotherapy directly to cancer cells while sparing most healthy tissue.

Trial Status

First patient dosed in March 2025. Initial Phase 1 data announced November 4, 2026, showing a 53% objective response rate in response-evaluable B-NHL patients. Full data to be presented at ASH 2026 in December 2026. The Phase 1 study continues enrollment.

The Two-Sided Case

▲ Bull Case5
Initial Phase 1 data showed a 53% objective response rate in heavily pretreated B-cell non-Hodgkin lymphoma patients, including complete responses, across all dose levels evaluated.
IM-1021 uses Immunome's proprietary TOP1 inhibitor payload (HC74), which the company says can overcome multiple mechanisms of ADC resistance, potentially differentiating it from competitors.
Analyst consensus is overwhelmingly bullish: 21 analysts with 6 Strong Buy and 15 Buy ratings, a mean price target of $35.20 (84.6% upside from $19.07), and only 2 Hold ratings.
Immunome reported $582.7M in cash as of Q2 2026, funding operations through 2028 and supporting pipeline acceleration across multiple ADC programs.
The ASH 2026 presentation in December provides a near-term data catalyst that could validate the platform and expand the addressable opportunity beyond lymphomas into solid tumors where ROR1 is expressed.
▼ Bear Case5
Phase 1 data is early and from a small, non-randomized dose-escalation cohort; response rates often shrink in larger expansion cohorts.
The ROR1-targeted ADC space is competitive, with Merck's zilovertamab vedotin (formerly VLS-101) and others already in development, raising the bar for differentiation.
Immunome's Q3 2026 loss of $0.76/share missed estimates by $0.13, and analysts cut price targets after the report, signaling near-term financial pressure.
Insider selling has been notable: CSO Jack Higgins sold $334k in September 2026 under a 10b5-1 plan, and CFO Isaac Barchas sold over $2.6M in August 2026.
Several large institutional holders trimmed or exited positions in Q2 2026, including Jefferies (exit), Polar Capital (exit), Marshall Wace (trim -66%), and T. Rowe Price (trim -38%).

Upcoming Catalysts

  • ASH 2026 conference presentation of detailed Phase 1 data (December 2026)
  • Potential expansion cohorts or dose-confirmation data readouts in 2027
  • Possible initiation of combination studies or solid tumor expansion

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Immunome Inc. 8-K IMNM ·Originating report

Sources · 9

Hover a chip for the title
1 aol.com2 ad-hoc-news.de3 morningstar.com4 businesswire.com5 bioworld.com6 businesswire.com7 msn.com8 businesswire.com9 seekingalpha.com